Measurement of Hormone Levels in Patients Receiving 17-HPC for Preterm Delivery

Completed

Conditions studied: Preterm Delivery

In brief

The purpose of this study is to measure hormones in the blood known to affect the timing of delivery after a single injection of 17-P in order to help understand its mechanism of action in preventing preterm delivery.

Key facts

Study ID

NCT00457886

Run by

Georgetown University

People needed

20

Starts

2005-07-01

Expected to finish

2007-06-01

Last updated by the study team

2017-03-09

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Spontaneous preterm delivery in a previous pregnancy, are between 15-20 weeks gestation during the current pregnancy, and have already decided whether or not to receive 17-alphahydroxyprogesterone caproate (17-P) for the prevention of preterm delivery.

You may not qualify if…

• Multiple gestation
• Known fetal anomaly
• Progesterone or heparin treatment during the current pregnancy
• Seizure disorder
• Pre-existing or gestational diabetes
• Hypertension requiring medication
• Thyroid or adrenal gland disorder

Where it is running

• Georgetown University Medical Center — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.